Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users With Renal Impairment: A Population-Based Cohort Study

Diabetes Care - Tập 37 Số 8 - Trang 2218-2224 - 2014
Willemijn L. Eppenga1,2, Arief Lalmohamed3,4, Arjen F.J. Geerts4, Hieronymus J. Derijks4,1, Michel Wensing2, Toine C. G. Egberts3,4, Peter A. G. M. De Smet5,2, Frank de Vries6,7,4
1Hospital Pharmacy ZANOB, ’s-Hertogenbosch, The Netherlands
2Scientific Institute for Quality of Healthcare, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
3Department of clinical pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
4Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
5Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
6Care and Public Health Research Institute (CAPHRI),, Maastricht, the Netherlands
7Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, the Netherlands

Tóm tắt

OBJECTIVE The objective of this study was to determine whether treatment with metformin in patients with renal impairment is associated with a higher risk of lactic acidosis or elevated lactate concentrations compared with users of a noninsulin antidiabetic drug (NIAD) who had never used metformin. RESEARCH DESIGN AND METHODS A cohort of 223,968 metformin users and 34,571 diabetic patients who had never used metformin were identified from the Clinical Practice Research Datalink (CPRD).The primary outcome was defined as either a CPRD READ code lactic acidosis or a record of a plasma lactate concentration >5 mmol/L. The associations between renal impairment, dose of metformin, and the risk of lactic acidosis or elevated lactate concentrations were determined with time-dependent Cox models and expressed as hazard ratios (HRs). RESULTS The crude incidence of lactic acidosis or elevated lactate concentrations in current metformin users was 7.4 per 100,000 person-years (vs. 2.2 per 100,000 person-years in nonusers). Compared with nonusers, risk of lactic acidosis or elevated lactate concentrations in current metformin users was significantly associated with a renal function <60 mL/min/1.73 m2 (adjusted HR 6.37 [95% CI 1.48–27.5]). The increased risk among patients with impaired renal function was further increased in users of ≥730 g of metformin in the preceding year (adjusted HR 11.8 [95% CI 2.27–61.5]) and in users of a recent high daily dose (>2 g) of metformin (adjusted HR 13.0 [95% CI 2.36–72.0]). CONCLUSIONS Our study is consistent with current recommendations that the renal function of metformin users should be adequately monitored and that the dose of metformin should be adjusted, if necessary, if renal function falls below 60 mL/min/1.73 m2.

Từ khóa


Tài liệu tham khảo

Wen, 2009, Impact of acute kidney injury on metformin-associated lactic acidosis, Int Urol Nephrol, 41, 967, 10.1007/s11255-009-9549-6

Arroyo, 2011, Metformin-associated acute kidney injury and lactic acidosis, Int J Nephrol, 749653

Nye, 2011, Metformin: the safest hypoglycaemic agent in chronic kidney disease?, Nephron Clin Pract, 118, c380, 10.1159/000323739

Graham, 2011, Clinical pharmacokinetics of metformin, Clin Pharmacokinet, 50, 81, 10.2165/11534750-000000000-00000

Klachko, 2011, Use of metformin in patients with kidney and cardiovascular diseases, Cardiorenal Med, 1, 87, 10.1159/000327151

Lalau, 2000, Metformin and lactic acidosis in diabetic humans, Diabetes Obes Metab, 2, 131, 10.1046/j.1463-1326.2000.00053.x

Salpeter, 2010, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, Cochrane Database Syst Rev, 4, CD002967

Renda, 2013, Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review, Eur Rev Med Pharmacol Sci, 17, 45

Duong, 2013, The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis, Drug Saf, 10.1007/s40264-013-0038-6

Brown, 1998, Lactic acidosis rates in type 2 diabetes, Diabetes Care, 21, 1659, 10.2337/diacare.21.10.1659

van Berlo-van de Laar, 2011, Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements, J Clin Pharm Ther, 36, 376, 10.1111/j.1365-2710.2010.01192.x

Bodmer, 2008, Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis, Diabetes Care, 31, 2086, 10.2337/dc08-1171

Rocha, 2013, Metformin in patients with chronic kidney disease: strengths and weaknesses, J Nephrol, 26, 55, 10.5301/jn.5000166

Friesecke, 2010, Outcome of severe lactic acidosis associated with metformin accumulation, Crit Care, 14, R226, 10.1186/cc9376

Lipska, 2011, Use of metformin in the setting of mild-to-moderate renal insufficiency, Diabetes Care, 34, 1431, 10.2337/dc10-2361

KNMP Royal Dutch Association for the Advancement of Pharmacy, 2012, Dutch guidelines for drug-dosing in chronic kidney disease

Scheen, 2013, Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes, Diabetes Metab, 39, 179, 10.1016/j.diabet.2013.02.006

Sambol, 1995, Kidney function and age are both predictors of pharmacokinetics of metformin, J Clin Pharmacol, 35, 1094, 10.1002/j.1552-4604.1995.tb04033.x

Lalau, 1999, Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations, Drug Saf, 20, 377, 10.2165/00002018-199920040-00006

Kajbaf, 2013, The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis., BMC Pharmacol Toxicol, 14, 22, 10.1186/2050-6511-14-22

Davis, 2001, The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study, Br J Clin Pharmacol, 52, 137, 10.1046/j.0306-5251.2001.01423.x

Lim, 2007, Lactate levels in Asian patients with type 2 diabetes mellitus on metformin and its association with dose of metformin and renal function, Int J Clin Pract, 61, 1829, 10.1111/j.1742-1241.2007.01487.x

Scale, 2011, Diabetes, metformin and lactic acidosis, Clin Endocrinol (Oxf), 74, 191, 10.1111/j.1365-2265.2010.03891.x

Stang, 1999, Incidence of lactic acidosis in metformin users, Diabetes Care, 22, 925, 10.2337/diacare.22.6.925

Kamber, 2008, Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study, Med J Aust, 188, 446, 10.5694/j.1326-5377.2008.tb01713.x

Howlett, 1999, A risk-benefit assessment of metformin in type 2 diabetes mellitus, Drug Saf, 20, 489, 10.2165/00002018-199920060-00003

Lester, 2010, Developing Quality and Outcomes Framework (QOF) indicators and the concept of ‘QOFability’, Qual Prim Care, 18, 103

Thông tin
Thông tin xuất bản

Diabetes Care

Tập 37 Số 8

2218-2224

Thông tin tác giả